Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27899553 | 0.85 | TSHR (0.38) | OPRM1OPRK1TSHRSMN1; SMN2LMNA | |
| SCHEMBL507495 | 0.83 | SMN1; SMN2 (0.44) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL29866080 | 0.83 | TSHR (0.39) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL6158666 | 0.83 | TSHR (0.39) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL29793660 | 0.83 | SMN1; SMN2 (0.44) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL11738540 | 0.82 | LMNA (0.36) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL1706364 | 0.81 | AKR1B1 (0.43) | TSHRLMNAMAPTGAAALDH1A1 | |
| SCHEMBL27652959 | 0.80 | TSHR (0.40) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL9050671 | 0.78 | NOS3 (0.37) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL4944584 | 0.78 | TAAR1 (0.38) | TSHRSMN1; SMN2LMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-115066428-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021143924-A1 | BORIC ACID DERIVATIVE | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| CN-102414168-B | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD | 2014-05-21 | — | — | CN | disclosed |
| CN-101903378-B | Aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD | 2014-03-12 | — | — | CN | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | disclosed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| CN-101903353-B | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2013-04-10 | — | — | CN | disclosed |
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | disclosed |
| CN-101903353-A | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | disclosed |
| CN-101903378-A | Aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| EP-2225231-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | OPRM1 3003/4885OPRD1 920/4885OPRK1 1137/4885 |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ADORA1, ADORA3, TBXA2R | OPRM1 639/4885OPRD1 190/4885OPRK1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.